Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sino Biopharm Licenses Rovadicitinib to Sanofi for up to $1.5B | Contract Pharma
Breaking News

Sino Biopharm Licenses Rovadicitinib to Sanofi for up to $1.5B

Rovadicitinib is approved in China for myelofibrosis and is in late-stage development for chronic graft-versus-host disease.

Sino Biopharmaceutical has signed an exclusive global licensing agreement ‌with Sanofi for the rights to rovadicitinib, in a transaction valued at up to $1.53 billion. The drug was recently approved in China as a first-line treatment for various forms of intermediate-2 or high-risk myelofibrosis and is in late-stage development for chronic graft-versus-host disease.

Under the agreement, Sanofi gains an exclusive worldwide license to develop, manufacture and commercialize rovadicitinib. Sino Biopharm will receive an upfront payment of $135 million and is eligible to receive potential development, regulatory and sales ‌milestones of as much as $1.4 billion.

Rovadicitinib is an oral JAK/ROCK inhibitor that targets inflammation and tissue scarring by blocking enzymes that drive both processes.

The deal is subject ⁠to customary closing conditions.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters